Plain-English translation of NCT06578507 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Sickle Cell Disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a medication called hydroxycarbamide in a new twice-daily form (dispersible tablets) designed for children with sickle cell disease. Researchers want to understand how the medication works in young bodies, whether it helps reduce sickle cell symptoms, and whether it's safe to use this way. Currently, hydroxycarbamide is given less frequently, so this trial explores whether more frequent dosing might be better for children.
Sickle cell disease causes significant pain and health complications in children. While this medication is already used to help manage the disease, researchers believe giving it twice daily in a child-friendly tablet form might work better and help more children benefit from treatment.
You likely qualify if…
You likely don't qualify if…
If you join this study, your child will take the medication twice every day for 12 months. You'll visit the clinic 7 times total — at the start, then at 1, 3, 6, 9, and 12 months — where doctors will check how the medication is working and whether it's safe through blood tests and other assessments. The tablet form is designed to be easier for children to take than standard pills.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
France